Covaxin to use ViroVax’s adjuvant Alhydroxiquim-II to boost immune response

By: |
October 5, 2020 1:35 PM

According to a press release issued by the city-based vaccine innovator, the technology is being used under a licensing agreement with Kansas-based ViroVax LLC.

The governor further said that the Centre's Ayushman Bharat scheme, which provides free healthcare services, has provided succour to many amid the crisis.

Vaccine maker Bharat Biotech on Monday announced its novel coronavirus vaccine (under development) Covaxin, which was approved for human trials, will use adjuvant Alhydroxiquim-II to boost immune response and longer lasting immunity.

According to a press release issued by the city-based vaccine innovator, the technology is being used under a licensing agreement with Kansas-based ViroVax LLC.

Covaxin is an inactivated vaccine derived from a strain of SARS-CoV-2 virus, isolated at the National Institute of Virology (NIV), Pune, an Indian virology research institute.

The inactivated virus is formulated with ViroVax’s adjuvant to produce the vaccine candidate, it said.

Bharat Biotech is currently conducting Phase II human trials of Covaxin after receiving approval from the Drug Controller General of India (DCGI).

“There is critical need for development and availability of adjuvants that elucidate mechanisms of action inducing greater antibody responses to vaccine antigens, thus resulting in long-term protection against pathogens. Adjuvants also enhance the sustainability of the global vaccine supply on account of their antigen-sparing effect,” Krishna Ella, Chairman and Managing Director of Bharat Biotech,said.

“Our partnership with ViroVax resonates with Bharat Biotech’s relentless efforts towards developing safe and effective vaccines coupled with long term immunity,” he added.

“ViroVax is delighted to partner with Bharat Biotech. This has been possible because of support from the National Institutes of Health,” Sunil David, Founder of ViroVax said.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Lockdown should be last resort: PM Modi
2Govt aid will help vaccine production, says Poonawalla
3Vaccine ramp-up: Advance of Rs 4,500 crore to be paid to SII, Bharat Biotech